Viridian Therapeutics Inc [VRDN] stock is trading at $18.66, up 0.48%. An important factor to consider is whether the stock is rising or falling in short-term value. The VRDN shares have gain 4.77% over the last week, with a monthly amount glided 8.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo downgraded its rating to Equal Weight on December 19, 2024, and dropped its price target to $27. On November 25, 2024, TD Cowen initiated with a Buy rating. Needham reiterated its Buy rating and increased its price target to $38 on September 11, 2024. Wolfe Research initiated its recommendation with a Outperform and recommended $29 as its price target on June 11, 2024. Goldman started tracking with a Buy rating for this stock on June 06, 2024, and assigned it a price target of $23. In a note dated May 09, 2024, Ladenburg Thalmann downgraded a Neutral rating on this stock.
Viridian Therapeutics Inc [VRDN] stock has fluctuated between $9.90 and $27.20 over the past year. Currently, Wall Street analysts expect the stock to reach $22.79 within the next 12 months. Viridian Therapeutics Inc [NASDAQ: VRDN] shares were valued at $18.66 at the most recent close of the market. An investor can expect a potential return of 22.13% based on the average VRDN price forecast.
Analyzing the VRDN fundamentals
Viridian Therapeutics Inc [NASDAQ:VRDN] reported sales of 0.30M for the trailing twelve months, which represents a growth of 4.17%. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at -1218.31%, Pretax Profit Margin comes in at -1128.07%, and Net Profit Margin reading is -1128.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.59, Equity is -0.55 and Total Capital is -0.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.20 points at the first support level, and at 17.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.13, and for the 2nd resistance point, it is at 19.61.
Ratios To Look Out For
For context, Viridian Therapeutics Inc’s Current Ratio is 11.01. On the other hand, the Quick Ratio is 11.01, and the Cash Ratio is 2.23. Considering the valuation of this stock, the price to sales ratio is 5079.40, the price to book ratio is 4.67.
Transactions by insiders
Recent insider trading involved Beetham Thomas W., Chief Operating Officer, that happened on Sep 27 ’24 when 5000.0 shares were purchased. President and CEO, Mahoney Stephen F. completed a deal on Sep 27 ’24 to buy 21400.0 shares. Meanwhile, Director Fairmount Funds Management LLC bought 1.6 million shares on Sep 13 ’24.
